Peptide Dendrons as Thermal-Stability Amplifiers for Immunoglobulin G1 Monoclonal Antibody Biotherapeutics
作者:Rohit Bansal、Sameer Dhawan、Soumili Chattopadhyay、Govind P. Maurya、V. Haridas、Anurag S. Rathore
DOI:10.1021/acs.bioconjchem.7b00389
日期:2017.10.18
Biotherapeutics such as monoclonal antibodies (mAbs) have a major share of the pharmaceutical industry for treatment of life-threatening chronic diseases such as cancer, skin ailments, and immune disorders. Instabilities such as aggregation, fragmentation, oxidation, and reduction have resulted in the practice of storing these products at low temperatures (−80 to −20 °C). However, reliable storage at these temperatures can be a challenge, particularly in developing and underdeveloped countries; hence, lately, there has been a renewed interest in creating formulations that would offer stability at higher temperatures (25 to 55 °C). Most therapeutic formulations contain excipients such as salts, sugars, amino acids, surfactants, and polymers to provide stability to the biotherapeutic, but their efficacy at high temperatures is limited. The current work proposes the use of peptide dendrons of different generations to create formulations that would be stable at high temperature. Among these dendrons, third-generation lysine dendron L6 has been identified to provide the highest stability to mAbs, as demonstrated by a host of analytical techniques such as size-exclusion chromatography (SEC), dynamic light scattering (DLS), Nanoparticle tracking Analysis (NTA), and circular dichroism (CD). The biocompatibility of these dendrons was confirmed by hemolytic activity tests. Non-interference of the dendrons with the activity of the mAb was confirmed using a surface plasmon resonance (SPR) based activity assay. We hope that this study will stimulate utilization of such higher-generation dendrons for enhancing the thermal stability of mAbs.
生物治疗药物如单克隆抗体(mAbs)在制药行业中占据重要份额,主要用于治疗癌症、皮肤疾病和免疫系统疾病等危及生命的慢性疾病。聚集、断裂、氧化和还原等不稳定性导致这些产品通常需要在低温(-80至-20°C)下储存。然而,在这些温度下可靠存储面临挑战,尤其是在发展中国家和欠发达国家。因此,最近人们对开发能够在较高温度(25至55°C)下保持稳定的配方产生了新的兴趣。大多数治疗性配方中含有盐、糖、氨基酸、表面活性剂和聚合物等辅料,以提供生物治疗药物的稳定性,但它们在高温下的有效性有限。本研究提出使用不同代际的肽树突状体来创建高温稳定的配方。在这些树突状体中,第三代赖氨酸树突状体L6被确定为提供对mAbs最高稳定性的材料,相关的分析技术如尺寸排阻色谱(SEC)、动态光散射(DLS)、纳米颗粒追踪分析(NTA)和圆二色谱(CD)均进行了验证。通过溶血活性测试确认了这些树突状体的生物相容性。通过基于表面等离子共振(SPR)的活性测定确认了树突状体与mAb活性之间不存在干扰。我们希望这项研究能促使人们利用这种高代树突状体来增强mAbs的热稳定性。